Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Who needs direct-acting antivirals for HCV? Challenges faced in advancing HCV therapy for HIV-HCV-coinfected individuals.

Antiviral therapy - 1 Jan 2013

Klein Marina B, Rollet Kathleen C, Hull Mark, Cooper Curtis, Walmsley Sharon, Conway Brian, Pick Neora

Abstract excerpt

BACKGROUND: The recent availability of new direct-acting antivirals (DAAs) for HCV treatment, which significantly increase sustained virological response rates for genotype 1 HCV infection, has brought new optimism with respect to curative HCV treatment for HIV-HCV-coinfected patients. We describe the characteristics of coinfected patients who could be eligible for DAAs to determine potential challenges facing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiretroviral Therapy, Highly Active
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Canada

Share to Coinfection

Share to Follow-Up Studies

Share to Hepacivirus

Share to Hepatitis C

Share to HIV Infections

Source

Identifiers

PMID: 23211632
DOI: 10.3851/IMP2484

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Who needs direct-acting antivirals for HCV? Challenges faced in advancing HCV therapy for HIV-HCV-coinfected individuals.PMID 23211632Read ↗

Advances in the treatment of HIV/HCV coinfection in adults.Semantic proximity Read ↗

Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014.Semantic proximity Read ↗

Direct-acting Antivirals for HIV/HCV Co-infected Individuals: As Good as it Gets?Semantic proximity Read ↗

HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?Semantic proximity Read ↗

Treatment of chronic HCV genotype 1 coinfection.Semantic proximity Read ↗

Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens.Semantic proximity Read ↗

Optimal therapy of HIV/HCV co-infected patients with direct acting antivirals.Semantic proximity Read ↗

Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study.Semantic proximity Read ↗

Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain.Semantic proximity Read ↗

Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy: A National Observational Cohort StudySemantic proximity Read ↗

Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting.Semantic proximity Read ↗

Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.